Singapore – December 30, 2025 – Luca Healthcare, a global leader in AI powered digital biomarkers and predictive healthcare solutions, today announced that its research on sound based biomarkers for respiratory disease has been accepted for presentation at the American Thoracic Society (ATS) International Conference 2026, taking place May 15–20, 2026 in Orlando, Florida. This milestone follows Luca’s recent recognition at the European Respiratory Society (ERS) Congress 2025, underscoring the company’s accelerating global momentum and scientific leadership in acoustic biomarker innovation.
The accepted presentation, titled “Auxiliary Diagnosis of COPD With Cough Search and Portable Spirometry: A Multicenter, Prospective, Comparative Validation Study,” will be featured at ATS 2026, one of the world’s most influential scientific gatherings for pulmonology, critical care, and respiratory innovation.
Driving Global Adoption of Sound and Movement Based Biomarkers
Respiratory diseases remain one of the most pressing global health challenges, with COPD alone responsible for millions of deaths annually and billions in economic burden. Traditional diagnostic pathways remain costly, infrastructure dependent, and inaccessible for large segments of the global population.
Luca Healthcare’s sound based biomarker platform is increasingly being adopted by pharmaceutical partners seeking scalable digital endpoints, remote patient monitoring, and predictive algorithms that enhance clinical trial efficiency and support earlier, more personalized intervention. Luca is also advancing movement based digital biomarkers, enabling objective, sensor driven assessment of gait, tremor, and motor function to further expand its portfolio of clinically meaningful endpoints. These multimodal algorithms are being integrated directly into May, Luca’s AI health agent, enabling real time, software based screening and monitoring that can be deployed globally at population scale.
By enabling continuous assessment using widely accessible data such as cough acoustics and movement signals, Luca’s technology offers a cost effective path to global screening and disease management – including in low resource settings where traditional diagnostics remain inaccessible.
A Strengthening Global Trajectory
“Being selected to present at ATS 2026 is another strong validation of our scientific rigor and the global relevance of our work,” said Echo Chen, Ph.D., CEO of Luca Healthcare. “We are continuing the momentum from ERS and gaining meaningful traction worldwide as sound and movement based biomarkers emerge as powerful tools for drug research, clinical development, and AI enabled healthcare delivery.”
About Luca Healthcare
Luca Healthcare is a global leader in AI powered digital biomarkers and predictive healthcare solutions. The company develops clinically validated, software based tools for screening, monitoring, and managing chronic diseases using multimodal sensor data, including voice, cough, movement, and vital signs. Through advanced algorithms and global partnerships, Luca Healthcare is redefining how diseases are detected, tracked, and treated – making high quality healthcare more accessible and affordable worldwide.